Acrivon Therapeutics Past Earnings Performance
Past criteria checks 0/6
Acrivon Therapeutics's earnings have been declining at an average annual rate of -56.5%, while the Biotechs industry saw earnings growing at 15.9% annually.
Key information
-56.5%
Earnings growth rate
29.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -59.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Revenue & Expenses Breakdown
How Acrivon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -64 | 23 | 48 |
| 31 Dec 23 | 0 | -60 | 21 | 46 |
| 30 Sep 23 | 0 | -50 | 20 | 36 |
| 30 Jun 23 | 0 | -45 | 15 | 34 |
| 31 Mar 23 | 0 | -37 | 12 | 28 |
| 31 Dec 22 | 0 | -31 | 9 | 24 |
| 30 Sep 22 | 0 | -27 | 6 | 21 |
| 30 Jun 22 | 0 | -20 | 5 | 15 |
| 31 Mar 22 | 0 | -19 | 3 | 16 |
| 31 Dec 21 | 0 | -16 | 2 | 14 |
Quality Earnings: ACRV is currently unprofitable.
Growing Profit Margin: ACRV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACRV is unprofitable, and losses have increased over the past 5 years at a rate of 56.5% per year.
Accelerating Growth: Unable to compare ACRV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACRV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: ACRV has a negative Return on Equity (-59.38%), as it is currently unprofitable.